Home Cart Sign in  
Chemical Structure| 1893397-65-3 Chemical Structure| 1893397-65-3

Structure of TBK1/IKKε-IN-5
CAS No.: 1893397-65-3

Chemical Structure| 1893397-65-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TBK1/IKKε-IN-5 is an orally active dual TBK1 and IKKε inhibitor with IC50 values of 1 nM and 5.6 nM, respectively. It enhances PD-1 blockade response and induces immune memory in rats when combined with anti-PD-L1, suitable for cancer and tumor immunity research.

Synonyms: compound 1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of TBK1/IKKε-IN-5

CAS No. :1893397-65-3
Formula : C28H31N7O3
M.W : 513.59
SMILES Code : N#CC1=C(OC2CCOCC2)C=CC(C3=NC=NC(NC4=CC=C(N5CCN(CC5)C6COC6)C=C4)=N3)=C1
Synonyms :
compound 1
MDL No. :MFCD32067990
InChI Key :QYQFLAQHGHBIFA-UHFFFAOYSA-N
Pubchem ID :118979674

Safety of TBK1/IKKε-IN-5

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of TBK1/IKKε-IN-5

pyroptosis
TLR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
IHUVECs 500 ng/mL 60 minutes To inhibit POSTN-induced endothelial cell migration and tube formation PMC10423747
Calu-3 cells 20 μM To evaluate the effect of ACBI1 on SARS-CoV-2 infection, results showed that ACBI1 significantly inhibited viral replication. PMC9885530
HL-60 (HL-HIG) 4 µM 24 hours Evaluate the reactivation capacity of IKK inhibitors in HIV latency models, showing MRT67307 and TPCA-1 induced 1.6-fold and 1.8-fold viral reactivation respectively PMC9741028
Jurkat (J-HIG) 4 µM 24 hours Evaluate the reactivation capacity of IKK inhibitors in HIV latency models, showing MRT67307 and TPCA-1 induced 1.6-fold and 1.8-fold viral reactivation respectively PMC9741028

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice GBM mouse model Intraperitoneal injection 100 mg/kg Once daily for 10 days To evaluate the effect of SR9009 on tumor angiogenesis PMC10423747
Mice MMTV-PyVMT transgenic mouse model Oral 15 mg/kg Once every three days, for 32 days To evaluate the effect of COMP1 on breast cancer cell lung metastasis, results showed that COMP1 significantly reduced lung metastasis of breast cancer cells. PMC9345937

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.95mL

0.39mL

0.19mL

9.74mL

1.95mL

0.97mL

19.47mL

3.89mL

1.95mL

References

 

Historical Records

Categories